• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：一项由研究者发起的单臂研究，评估玻璃体内注射阿柏西普对曾接受雷珠单抗或贝伐单抗治疗的渗出性年龄相关性黄斑变性患者的疗效、安全性及耐受性（ASSESS研究）：12个月分析 [更正]

Erratum: A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum].

出版信息

Clin Ophthalmol. 2017 Feb 7;11:303. doi: 10.2147/OPTH.S116038. eCollection 2017.

DOI:10.2147/OPTH.S116038
PMID:28223773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5304975/
Abstract

[This corrects the article on p. 1759 in vol. 9, PMID: 26445522.].

摘要

[这更正了第9卷第1759页上的文章， PMID: 26445522。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee11/5304975/5f331786d788/opth-11-303Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee11/5304975/5f331786d788/opth-11-303Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee11/5304975/5f331786d788/opth-11-303Fig4.jpg

相似文献

1
Erratum: A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum].勘误：一项由研究者发起的单臂研究，评估玻璃体内注射阿柏西普对曾接受雷珠单抗或贝伐单抗治疗的渗出性年龄相关性黄斑变性患者的疗效、安全性及耐受性（ASSESS研究）：12个月分析 [更正]
Clin Ophthalmol. 2017 Feb 7;11:303. doi: 10.2147/OPTH.S116038. eCollection 2017.
2
A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis.一项由研究者发起的单臂研究，旨在评估玻璃体内注射阿柏西普对曾接受雷珠单抗或贝伐单抗治疗的渗出性年龄相关性黄斑变性患者的疗效、安全性和耐受性（ASSESS研究）：12个月分析。
Clin Ophthalmol. 2015 Sep 22;9:1759-66. doi: 10.2147/OPTH.S87043. eCollection 2015.
3
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.阿柏西普治疗对雷珠单抗和/或贝伐单抗治疗仍有渗出性 AMD 伴持续性积液。
Br J Ophthalmol. 2013 Aug;97(8):1032-5. doi: 10.1136/bjophthalmol-2013-303344. Epub 2013 Jun 13.
4
Initial utilization of aflibercept in exudative age-related macular degeneration.阿柏西普在渗出性年龄相关性黄斑变性中的初始应用。
Eur J Ophthalmol. 2014 Jul-Aug;24(4):576-81. doi: 10.5301/ejo.5000421. Epub 2014 Mar 17.
5
Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).对于先前接受雷珠单抗或贝伐单抗治疗渗出性年龄相关性黄斑变性的患者，转换为阿柏西普治疗6个月后的光学相干断层扫描和视力结果（美国眼科学会论文）
Trans Am Ophthalmol Soc. 2014 Jul;112:160-98.
6
Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.玻璃体内注射阿柏西普治疗先前接受过玻璃体内注射雷珠单抗治疗的渗出性年龄相关性黄斑变性患者的眼睛。
Indian J Ophthalmol. 2015 Nov;63(11):832-6. doi: 10.4103/0301-4738.171964.
7
Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.玻璃体内注射阿柏西普或雷珠单抗前后年龄相关性黄斑变性患者血管内皮生长因子的全身水平：一项随机、前瞻性试验。
Acta Ophthalmol. 2015 Mar;93(2):e154-9. doi: 10.1111/aos.12604. Epub 2014 Dec 8.
8
A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.玻璃体内注射贝伐单抗、雷珠单抗或阿柏西普治疗新生血管性年龄相关性黄斑变性的疗效比较。
Int Ophthalmol. 2017 Oct;37(5):1205-1214. doi: 10.1007/s10792-016-0391-4. Epub 2016 Nov 8.
9
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.阿柏西普治疗对贝伐单抗和雷珠单抗抵抗的渗出性年龄相关性黄斑变性。
Am J Ophthalmol. 2013 Jul;156(1):15-22.e1. doi: 10.1016/j.ajo.2013.02.017. Epub 2013 May 22.
10
Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.玻璃体内注射阿柏西普治疗对贝伐单抗或雷珠单抗耐药的糖尿病性黄斑水肿患者：对阿柏西普反应的分析
Asia Pac J Ophthalmol (Phila). 2017 May-Jun;6(3):250-255. doi: 10.22608/APO.2016186. Epub 2017 Apr 10.